Risk Factors for Tremor in a Population of Patients with Severe Mental Illness: An 18-year Prospective Study in a Geographically Representative Sample (The Curacao Extrapyramidal Syndromes Study XI) by Mentzel, Charlotte L. et al.
Articles
Risk Factors for Tremor in a Population of Patients with Severe Mental Illness:
An 18-year Prospective Study in a Geographically Representative Sample
(The Curacao Extrapyramidal Syndromes Study XI)
Charlotte L. Mentzel
1,2*
, P. Roberto Bakker
1,2




, Michiel R. H. van den Oever
4





, Marina AJ Tijssen
9
& Peter N. van Harten
1,2
1 Department of Psychiatry and Psychology, Maastricht University Medical Centre, South Limburg Mental Health and Teaching Network, Maastricht, The Netherlands,
2 Psychiatric Centre GGZ Centraal, Amersfoort, The Netherlands, 3 King’s College London, King’s Health Partners, Department of Psychosis Studies, Institute of Psychiatry,
London, UK, 4 Psychiatric Centre GGZ Drente, Assen, The Netherlands, 5 Psychiatric Centre GGz Curaçao, Groot Kwartier, Curacao, 6 Parnassia Psychiatric Institute,
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Abstract
Background: The aim was to assess incidence, prevalence and risk factors of medication-induced tremor in African-Caribbean patients with severe mental illness (SMI).
Method: A prospective study of SMI patients receiving care from the only mental health service of the previous Dutch Antilles. Eight clinical assessments, over 18 years,
focused on movement disorders, medication use, and resting tremor (RT) and (postural) action tremor (AT). Risk factors were modeled with logistic regression for both current
(having) tremor and for tremor at the next time point (developing). The latter used a time-lagged design to assess medication changes prior to a change in tremor state.
Results: Yearly tremor incidence rate was 2.9% and mean tremor point prevalence was 18.4%. Over a third of patients displayed tremor during the study. Of the
patients, 5.2% had AT with 25% of cases persisting to the next time point, while 17.1% of patients had RT of which 65.3% persisted. When tremor data were
examined in individual patients, they often had periods of tremor interspersed with periods of no tremor.
Having RT was associated with age (OR51.07 per year; 95% confidence interval 1.03–1.11), sex (OR50.17 for males; 0.05–0.78), cocaine use (OR510.53;
2.22–49.94), dyskinesia (OR50.90; 0.83–0.97), and bradykinesia (OR51.16; 1.09–1.22). Developing RT was strongly associated with previous measurement RT
(OR59.86; 3.80–25.63), with previous RT severity (OR51.22; 1.05–1.41), and higher anticholinergic load (OR5 1.24; 1.08–1.43).
Having AT was associated with tremor-inducing medication (OR5 4.54; 1.90–10.86), cocaine use (OR514.04; 2.38–82.96), and bradykinesia (OR51.07;
1.01–1.15). Developing AT was associated with, previous AT severity (OR52.62 per unit; 1.64–4.18) and tremor reducing medication (OR50.08; 0.01–0.55).
Conclusions: Long-stay SMI patients are prone to developing tremors, which show a relapsing–remitting course. Differentiation between RT and AT is
important as risk factors differ and they require different prevention and treatment strategies.
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Introduction
Tremors are rhythmic, involuntary, oscillatory movements of body
parts.1 In clinical psychiatric practice tremor is one of the most
frequently occurring movement disorders2 most often as a side effect of
medication.3 Tremor negatively influences quality of life, contributes
to stigmatization,2 and is an important reason for medication non-
compliance.2,3
Tremors can be divided into resting tremor (RT) and action tremor
(AT). AT can be further subdivided into postural, simple kinetic, and
intention tremor.4 In the literature, lithium, mood stabilizers, and
antidepressants are described in relation to postural action tremors,
which occur during voluntary muscle contraction or suspension against
gravity2,5 with a frequency of 4–12 Hz.4 In contrast, antipsychotics
appear to be associated more with parkinsonism with RT as part of its
triad.1,6 RT has a frequency of between 3 and 6 Hz and occurs when
the affected limb, usually the hand, is fully supported against gravity.4
In general, patients with severe mental illness (SMI) are at high risk
for developing movement disorders, given the fact that they are often
exposed both to high doses and to polypharmacy.7–9 Movement
disorders include akathisia (4.5–9.3% prevalence7,10,11) tardive dyski-
nesia (28.4–39.7% prevalence7,10), dystonia (5.7–13.4% prevalence10),
and parkinsonism (36.1–56.2%7,10 prevalence). To our knowledge, no
articles have been published focusing on tremor in SMI patients.
Figures on tremor incidence and prevalence in SMI populations are
difficult to find. While the literature suggests that about 40–50% of
patients with medication-induced parkinsonism develop some form of
tremor,12 the incidence has never been studied. In addition, very little
is known about risk factors for development and cessation of tremor in
SMI populations.
The Curacao Extrapyramidal Syndromes study represents an 18-year
follow-up of the SMI patients in a geographically circumscribed
area.10,13,14 The database represents a valuable opportunity to pro-
spectively study tremor subtypes in a complete sample of SMI patients,




The protocol was approved by the Curaçao Institutional Review
Board, and written informed consent was obtained by a psychiatrist
from each patient. All patients were considered capable of making the
decision to take part in the trial themselves, as the study had no risks
for patients, required only a small time investment, and had possible
benefits. Details on the Curacao Extrapyramidal Syndromes study,
a longitudinal cohort study spanning eight measurements over 18 years,
have been published in previous reports.10,13,14 At baseline, data were
gathered pertaining to all SMI patients (223) receiving care from the
Capriles Hospital, the only psychiatric hospital in the Dutch Antilles
and providing services to all patients with psychotic disorders on the
islands. A baseline measurement was carried out in 1992 (N5162)
followed by seven follow-up visits in 1993 (N5149), 1994 (N5129),
1996 (N598), 1997 (N594), 1998 (N587), 2001 (N5114), and 2009
(N587). Loss to follow-up was rare as patients rarely moved out of the
catchment area and was mainly due to death. Inclusion criteria were
1) a history of antipsychotic medication use for at least 3 months; and
2) no obvious organic disorders that could cause movement disorders,
such as Parkinson’s disease. Essential tremor was not an exclusion
criterion. Movement disorders were rated on 1) the Unified Parkinson’s
Disease Rating Scale (UPDRS)15 for tremor, bradykinesia, and rigidity;
2) the Abnormal Involuntary Movement Scale (AIMS)16 for tardive
dyskinesia; and 3) the Barnes Akathisia Rating Scale (BARS)17 for
akathisia. Rating was achieved by consensus and the inter-rater
reliability kappa for tremor was 0.70; a detailed description of the test
situation can be found in previous publications.10 The UPDRS version
3.0 only includes the postural subtype of AT; hence, all AT in this
article are postural. All movement disorders were assessed in person by
the same two raters (P.v.H and G.M.), both psychiatrists specialized in
movement disorders in psychiatry; medication data and diagnosis were
extracted from patient records by trained clinicians and all patients
gave informed consent. Patients with mental retardation (N53) and
dementia (N57) were excluded as they were not considered SMI
disorders. Patients who had undergone a lobotomy (N522) were also
excluded. This resulted in a dataset of 191 SMI patients; 162 patients
were included at T0 and a further 29 (SMI day treatment patients)
were included at T1.
Demographic variables such as age, sex, DSM-III-R (Diagnostic
and Statistical Manual of Mental Disorders, Third Edition, Revised)
diagnosis, and cocaine use were collected from records at time of inclu-
sion. Medication data were collected at all time points and were converted
to defined daily doses (DDDs).18 Information on the type of antipsychotic,
i.e., first-generation antipsychotic or second-generation antipsychotic,
and the route of administration, oral or depot, was collected. The total
anticholinergic load of the combined medication was calculated for each
patient by summing the anticholinergic load pertaining to each medica-
tion according to the Anticholinergic Drug Scale (ADS).19 The ADS
assigns a score to each medication (ranging from 0 to 3) in accordance
with the level of anticholinergic action of the compound.
Tremor-protective medication was defined as beta-blockers (pro-
pranolol and sotalol) and dopamine agonists (levodopa and carbidopa).
Lithium, antidepressants and other medication were considered
tremor inducing if they were listed by Arbaizar et al.,2 Morgan and
Sethi,3 Puschmann and Wszolek,5 and Zeng et al.20 or had at least
1% risk of tremor according to the Dutch pharmaceutical reference
manual.21 Antipsychotics were not included in this category as they
were already represented separately in the total antipsychotic DDD.
RT was dichotomously defined as a severity score of at least mild
(a score of 2, range 0–4) on the RT subscale (item 3) and AT as a
severity score of at least mild on the AT subscale (item 4) of the
UPDRS.15 Movement disorder variables were continuous and defined
as 1) the sum of items 1–7 of the AIMS for tardive dyskinesia; 2) item 4
of the BARS for akathisia; 3) the sum of the sub items of item 5 of the
UPDRS for rigidity; and 4) the sum of items 1, 2, 6–12, and 14 of the
UPDRS for bradykinesia.
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Descriptive statistics
At each time point prevalence was calculated. In addition, the
18-year average prevalence was calculated over all time points. Incidence
rates were calculated by dividing the number of new cases by the number
of person-years of follow-up.
Regression models
All analyses were performed using STATA.22 As all assessments of
each subject were included in the analyses, data had a multilevel
structure with multiple assessments clustered within subjects. The Stata
xtlogit command is ideally suited to analyze this type of data. The
obtained odds ratios can be interpreted as odds ratio results obtai-
ned from unilevel logistic regression. The dependent variable was the
dichotomized tremor variable. Effect sizes of the risk factors were
expressed as odds ratios and their 95% confidence interval (CI). To
assess which factors were related to the development or cessation of a
tremor type over time, a time-lagged analysis was performed, using the
xtlogit random effects procedure. In this analysis, the dichotomous
tremor type was the outcome, while the same dichotomous tremor
type and clinician-influenced variables at the previous time point were
entered as independent variables.
Results
Demographic characteristics
Of the 191 patients included, 162 were included at baseline and
29 were included at the first follow-up measurement, resulting in a
total of 876 observations. Most (95.4%) were of African-Caribbean
origin. At baseline, mean age was 50 (SD 16) years; men were 47 (SD 14)
and women 58 (SD 19) years. The primary diagnoses according to
DSM-III-R were schizophrenia (80.2%), affective disorder (5.1%), and
other (14.7%). Information about medication use at baseline is displayed
in Table 1.
Tremor prevalence and incidence
Over a third of patients had tremor at least once during the study.
Overall, the average prevalence of the combined RT and AT outcome
(hereafter combined tremor) was 18%, with a time-specific distribution
of 15%, 23%, 25%, 18%, 16%, 13%, 21%, and 15% over the con-
secutive time points. RT occurred at an average prevalence of 17%,
with a time-specific distribution of 14%, 21%, 22%, 18%, 15%, 13%,
20%, and 14% over the consecutive time points. AT had a lower rate
at an average prevalence of 5% and a time-specific distribution of 4%,
3%, 7%, 2%, 6%, 2%, 11%, and 7% over the consecutive time points.
Longitudinally, tremors displayed a relapsing–remitting course; in
two-thirds of cases the combined tremor at one time point was also
present at the next time point. AT persisted less frequently than RT
(25% and 67% persistence to next time point, respectively). Incidence
rates were 29 per 1000 person-years (2.9%) for all tremors; 26 per
1,000 person-years, or 2.6% (95% CI 1.9–3.6%), for RT and 12 per
1000 person-years, or 1.2% (95% CI 0.8–1.9%), for AT. The number of
patients displaying a first time tremor is balanced by the number of
patients permanently remitting for tremor resulting in a flat tremor
prevalence over time despite the incidence of new tremor cases.
Risk factor analysis
The results of the risk factor analyses are described in Table 2.
Three separate analyses were done: one on combined tremor, one on
RT and AT types.
The combined tremor analysis
The multilevel logistic regression yielded significant odds ratios (OR)
between combined tremor and age (OR 1.06 per year), sex (reference
male; OR 0.18) and cocaine use (OR 8.32) Of the other movement
disorders, bradykinesia (OR 1.14 per unit UPDRS increase), but
not rigidity (OR51.09), was positively associated with tremor while
dyskinesia (OR 0.92 per unit AIMS increase) displayed a negative
association. Of the medication variables, only the number of tremor-
inducing medications (OR 2.23 per added medication) was signifi-
cantly associated with tremor.
Tremor subtype analysis
Cocaine use (OR 10.53 for RT and 14.04 for AT) and bradykinesia
(OR 1.16 for RT and 1.07 for AT) were associated with both tremor
types. Age (OR 1.07), sex (OR 0.19), and dyskinesia (OR 0.90) were
associated only with RT. Although for age and sex the odds ratio
is similar in both tremor types, the number of AT cases, however,
is smaller than the number of RT cases (48 AT cases versus 161 RT
cases). The number of tremor-inducing medications other than
antipsychotics (OR 4.54) was significantly associated only with AT.
Time-lagged regression analysis
The results of the time-lagged analyses are described in Table 3. For
the combined tremor analysis, previous combined tremor (OR 7.87)
and previous tremor severity (OR 1.20 per point on the UPDRS) were
significantly associated with current tremor. Of the medication
variables, previous higher anticholinergic load was associated with
more tremor (OR 1.19), whereas previous depot medication (OR 0.29)
was associated with less tremor.
In the tremor RT and AT subtype analysis only previous tremor
severity was significantly associated with both subtypes. RT was strongly
associated with previous RT (OR 9.86), but previous AT was not
significantly associated with previous AT (OR 0.24). Medication variables
also had different effects on resting and action tremors compared with the
combined tremor. Previous number of tremor-reducing medications (OR
0.08 per medication) was negatively associated with AT at the next time
point. Previous depot medication did not predict either type of tremor
subtype; however, the effect size for RT (0.33) was similar to the effect
size for the combined tremor outcome (0.29).
Discussion
To our knowledge this is the first long-term follow-up study on
medication-induced tremor in SMI patients, which demonstrates that
tremor is a frequently occurring relapsing–remitting disorder with over
Risk Factors for Tremor in Severe Mental Illness Mentzel CL, Bakker PR, van Os J, et al.
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services3
Table 1. Demographic Characteristics, Movement Disorder Prevalence, and Medication Use at Baseline
No Tremor Resting Tremor1 Action Tremor1 All Patients
N %* N %* N %* N %*
Demographic variables
Subjects 137 85 22 14 6 4% 162 100%
Age, mean SD 50.12 16.77 50.17 13.48 58.28 19.45 50.43 16.45
Male sex 94 69% 20 91% 5 83% 116 72%
Cocaine use 23 17% 5 23% 1 17% 28 17%
Diagnosis schizophrenia 112 82% 17 77% 3 50% 130 80%
Movement disorders
Dyskinesia 19 14% 3 14% 1 17% 22 14%
AIMS mean SD 6 4.11 6 4.58 2 6 4.06
Akathisia 5 11% 1 5% 0 0% 16 10%
BARS mean SD 2.53 0.74 4 2.63 0.81
Bradykinesia 32 23% 9 41% 4 67% 42 26%
UPDRS2 mean SD 14.81 6.71 15.22 8.89 19 7.53% 14.93 7.03
Rigidity 22 16% 7 32% 2 33% 29 18%
UPDRS3 mean SD 8.64 3 6.71 3.77 9.5 3.54% 8.17 3.24
Medication variables
Antipsychotic type
No AP 16 12% 0 0% 1 17% 17 10%
FGA only 115 84% 20 91% 4 67% 137 85%
SGA only 5 4% 2 9% 1 17% 7 4%
Both AP types 1 1% 0 0% 0 0% 1 1%
AP DDD mean SD 1.58 1.48 2.05 1.88 1.12 0.78 1.62 1.53
Depot use 81 59% 15 68% 3 50% 97 60%
Tremor-inducing
medication use
37 27% 4 18% 2 33% 43 27%
Tremor-reducing
medication use
3 2% 0 0% 0 0% 3 2%
Anticholinergic load 2.58 2.55 3.41 2.54 3.5 1.97 2.72 2.55
Benzodiazepine DDD 0.23 0.64 0.34 0.7 0.08 0.2 0.24 0.64
Abbreviations: AIMS, Abnormal Involuntary Movement Scale; AP, Antipsychotic; BARS, Barnes Akathisia Rating Scale; DDD, Defined Daily Dose;
FGA, First-generation Antipsychotic; SGA, Second-generation Antipsychotic; UPDRS, Unified Parkinson’s Disease Rating Scale.
1Patients can have both action and resting tremor.
2List items bradykinesia.
3List items rigidity.
*Numbers in percentages except when stated otherwise.
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a third of patients having tremor at least once during the 18 years of
the follow-up. In two-thirds of the SMI patients tremors were present
at the next assessment with the more severe tremor forms being more
likely to be present at the next time point. The importance of the
distinction in RT and AT should be noted, as each tremor type
is associated with different medication and demographic variables.
Tremor is highly noticeable and is often associated with shame, stigma,
and physical handicap; active assessment, treatment and prevention of
tremor is therefore of great clinical importance.2,3
Since most previous studies used a cross-sectional model and did
not focus on the vulnerable subgroup of SMI patients, it is difficult
to compare prevalence rates. Bakker et al.7 found an average of 20%
for combined tremor prevalence and a prevalence of 14% and 16%
for RT and AT respectively. The higher AT prevalence could be
Table 2. Relationship between Covariates and Tremor Subtypes in Psychiatric Patients with Severe Mental Illness, 18-year Follow-up Data
Any Tremor Resting Tremor Action Tremor
OR 95% CI OR 95% CI OR 95% CI
Demographic variables
Age 1.06** 1.02 1.10 1.07** 1.03 1.11 1.05 1.00 1.11
Sex 0.18* 0.05 0.69 0.19* 0.05 0.78 0.18 0.032 1.07
Cocaine use 8.32** 2.01 34.4 10.53** 2.22 49.94 14.04** 2.38 82.96
Diagnosis 2.42 0.66 8.87 2.17 0.53 8.90 2.26 0.49 10.35
Other movement disorders
Dyskinesia 0.92* 0.86 0.99 0.90** 0.83 0.97 1.04 0.95 1.15
Akathisia 1.32 0.88 1.98 1.30 0.84 2.01 1.34 0.74 2.44
Bradykinesia 1.14*** 1.08 1.21 1.16*** 1.09 1.22 1.07* 1.01 1.15
Rigidity 1.09 0.99 1.21 1.09 0.98 1.22 1.10 0.96 1.27
Medication variables
Benzodiazepine DDD 1.18 0.77 1.81 1.14 0.70 1.84 1.37 0.78 2.38
No antipsychotic use
(base 5 only FGA) 0.57 0.13 2.51 0.54 0.11 2.57 1.75 0.27 11.51
Only SGA use
(base 5 only FGA) 0.42 0.11 1.56 0.51 0.13 2.01 1.00 0.17 5.76
Both FGA and SGA
(base 5 only FGA) 0.48 0.11 2.08 0.47 0.10 2.42 0.69 0.09 5.23
Antipsychotic DDD 1.12 0.84 1.48 1.13 0.84 1.53 0.97 0.66 1.45
Depot use (base5 no) 2.15 0.90 5.17 2.14 0.85 5.40 1.65 0.47 5.81
Number of tremor inducing
medications 2.23* 1.10 4.52 1.83 0.86 3.92 4.54*** 1.90 10.86
Number of tremor reducing
medications 0.71 0.09 5.76 0.45 0.05 4.21 5.94 0.63 55.94
Anticholinergic load 0.99 0.85 1.16 0.97 0.82 1.15 1.15 0.93 1.42
Abbreviations: CI, 95% Confidence Interval; DDD, Defined Daily Dose; OR, Odds Ratio; FGA, First-generation Antipsychotic; SGA, Second-
generation Antipsychotic.
*p,0.05; **p,0.01; ***p,0.001.
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attributed to a different composition of the population. In the study by
Bakker et al. 13.5% of patients had an affective disorder as primary
diagnosis, in contrast to only 5.1% of patients in the current study.
While Bakker et al. did not collect data on antidepressant and lithium
use, both medications known to induce AT, it is to be expected that
they would be prescribed more frequently than in the current study.
The relapsing–remitting course of both tremor subtypes indicates
that environmental factors, such as medication or cocaine use, play an
important role in the development and cessation of tremor. The
relationship between age and RT is in line with previous research.3
The association between cocaine use and both tremor types has been
described before,2,3 whereas the association between sex and parkin-
sonism is found inconsistently.12
The risk factor analysis in the current study further underlines the
difference between RT and AT by their difference in association with
other movement disorders. As RT is part of the parkinsonism triad (RT,
bradykinesia, and rigidity),6 it is associated with bradykinesia as expected.
However, RT was not associated with rigidity, even though the relation-
ship between drug-induced parkinsonism and rigidity has been extensively
described.12,23 This could be in line with the subdivision of Parkinson’s
disease in tremor-dominant and rigidity-gait disturbance subtypes, which
have different underlying neuropathological mechanisms.24
There was also a significant association between AT and brady-
kinesia. Medication-induced parkinsonism can sometimes present with
postural action rather than RT12 and with more severe tremors it
is sometimes difficult to differentiate between the tremor types.4
Dyskinesia on the other hand was solely and inversely associated with
RT as described in other studies25 and is sometimes suggested that
parkinsonism and dyskinesia are at the other ends of the spectrum of
basal ganglia disorders.6
AT was associated with medication, other than antipsychotics,
known to induce tremor, as has been extensively described in the
literature.2,3 However, no relationship was found between RT and
antipsychotic type or dose, even though antipsychotic medication is
considered a primary cause for drug-induced parkinsonism.12,23 The
most likely explanation is that the effect of antipsychotic dose on
tremor is obscured due to the high doses of antipsychotics most
patients receive.
The time-lagged analysis was added to ascertain if there was the
temporal relationship between adapting medication and a subsequent
change in tremor status. This temporal relationship is one of the
Bradford Hill guidelines26 and is an argument for causality. The fact
that there seems to be a strong relationship (OR 0.08) between adding
a beta-blocker and the cessation of AT makes it highly likely that
Table 3. Time-lagged Relationship between Covariates and Tremor Subtypes in Psychiatric Patients with Severe Mental Illness, 18-year
Follow-up Data
All Tremor Rest Tremor Action Tremor
OR 95% CI OR 95% CI OR 95% CI
Having tremor at the previous
time point
7.87*** 3.45 17.94 9.86*** 3.80 25.63 0.24 0.03 1.96
Severity of tremor 1.20*** 1.08 1.34 1.22** 1.05 1.41 2.62*** 1.64 4.18
Medication variables
Change in benzodiazepine dose 0.90 0.68 1.28 0.72 0.48 1.08 1.59 0.91 2.79
Change in antipsychotic dose 0.88 0.67 1.14 0.91 0.69 1.20 0.98 0.68 1.43
Switching antipsychotics 0.84 0.38 1.89 0.70 0.29 1.68 0.79 0.21 2.98
Getting depot medication 0.29* 0.09 0.94 0.33 0.10 1.09 0.89 0.14 5.52
Stopping depot medication 1.97 0.60 6.50 2.04 0.60 6.94 1.90 0.29 12.32
Number of tremor inducing
medications 0.56 0.30 1.06 0.67 0.34 1.34 0.45 0.17 1.18
Number of tremor reducing
medications 0.27 0.04 1.71 0.63 0.11 3.72 0.08* 0.01 0.55
Anticholinergic load 1.19* 1.04 1.37 1.24** 1.08 1.43 1.10 0.88 1.38
Abbreviations: CI, 95% Confidence Interval; DDD, Defined Daily Dose; OR, Odds Ratio; FGA, First-generation Antipsychotic; SGA, Second-
generation Antipsychotic.
*p,0.05; **p,0.01; ***p,0.001.
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there is a causal relationship. The time-lagged models also showed
a strong association between previous tremor severity and previous
tremor. There was also a relationship between any type of tremor and
receiving depot medication. Because this relationship could not be
replicated in the tremor subtypes it is possible that this relationship is
spurious. It is also possible that the small number of depot changes has
left this variable underpowered.
Surprisingly, a higher anticholinergic load led to a higher risk of
tremor in the following assessment, for which different explanations
could be given. Firstly, clinicians might treat the parkinsonism
spectrum of bradykinesia and RT12 with an anticholinergic high
enough to reduce bradykinesia but not to reduce RT, owing to anti-
cholinergic side effects, such as a dry mouth, constipation, cognitive
problems. Secondly, anticholinergics may not be entirely effective
in treating RT in SMI patients. Mena and Yébenes,23 Caroff et al.27,
and Dayalu and Chou28 noted the paucity of evidence supporting
anticholinergic treatment of drug-induced parkinsonism. Mena and
Yébenes even stated that there is little rational for it.
Strengths
The inclusion of all inpatients (and outpatient clinic treatment
patients) of a restricted area reduces selection bias. Second, the long
follow-up period of 18 years with eight assessments over time increases
the validity of the findings. Third, loss to follow-up, which mainly
was by death, was limited, further reducing selection bias. Last, all
measurements were done by the same two raters, both psychiatrists
specializing in movement disorders (P.v.H. and G.M.), increasing the
reliability.
Limitations
The study population was already ill and taking antipsychotics for,
on average, 20 years before inclusion. For an incidence study it would
be more appropriate to include a population with no history of
psychopharmacology. Prevalence and risk factors for persistence, as
described in this article, may be more suitable to describe a relapsing–
remitting disorder such as tremor in a SMI population. Secondly, the
UPDRS does not really provide an in-depth examination of tremor, as
it focuses on parkinsonism symptoms as a whole. For this study a rating
scale focusing solely on tremor would have been better suited.
However, the UPDRS is a valid and reliable rating scale that measures
each of the three core symptoms of parkinsonism: bradykinesia,
rigidity, and tremor. Thirdly, it may be argued that a slight (score 1,
range 0–5) rest tremor is already abnormal and the cut off for RT
should therefore be lowered from mild (score 2) to slight. We examined
the results of lowering the cut off in a post hoc analysis and found that
this resulted in more extreme odds ratios and lower p-values for the
variables in the risk analysis. In the time-lagged analysis the same
occurred for previous tremor status and previous tremor severity.
However, the relationship between anticholinergic load and rest
tremor now has a p-value of 0.51 making it non-significant. Also
essential tremor was not an exclusion criterion for the study as in
the time-lagged analysis design; patients are their own controls and a
pre-existing tremor should not influence results. When the analyses are
redone excluding the four patients who had a pre-existing AT results
are nearly identical. Finally it would have been preferable to ascertain
cocaine use not only via medical records but also via urine toxicology
and to also register patient alcohol use.
In conclusion, medication-induced tremor is a frequently occurring
relapsing-remitting disorder with serious adverse effects for patients.
For clinicians it is important to differentiate between postural action
and RTs as both are caused by different types of medication and
require different treatment.
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